{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:23:07Z","timestamp":1756902187623,"version":"3.44.0"},"reference-count":11,"publisher":"The Pediatric Pharmacy Association","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Oseltamivir is a neuraminidase inhibitor that is labeled for prophylaxis and treatment of influenza. We describe a previously healthy 4-month-old infant who tested positive for influenza A and was started on oseltamivir. One hour after receiving his first dose of oseltamivir, the infant had a diaphoretic episode and appeared grey and clammy. The infant was subsequently seen by the primary care physician and referred for admission to the hospital. Approximately 40 minutes after the second dose of oseltamivir in the hospital, the infant's heart rate rose to greater than 300 bpm. An electrocardiogram was suggestive of supraventricular tachycardia. At the time of the event, the infant received 2 doses of adenosine, and oseltamivir was discontinued prior to transfer to a tertiary facility for a higher level of care.<\/jats:p>","DOI":"10.5863\/1551-6776-25.7.654","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T23:36:34Z","timestamp":1601422594000},"page":"654-657","source":"Crossref","is-referenced-by-count":2,"title":["Oseltamivir-Associated Supraventricular Tachycardia in an Infant"],"prefix":"10.5863","volume":"25","author":[{"given":"Emily C.","family":"Bodo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelley H.","family":"Shultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"year":"2018","series-title":"Tamiflu (oseltamivir) [package insert]","key":"i1551-6776-25-7-654-b1","unstructured":"Tamiflu (oseltamivir) [package insert]. South San Francisco, CA: Genentech Inc; 2018."},{"issue":"4","key":"i1551-6776-25-7-654-b2","series-title":"Pediatrics","first-page":"e1089","article-title":"Recommendations for prevention and control of influenza in children, 2013\u20132014","volume":"132","year":"2013","unstructured":"Committee on Infectious Diseases.\n          Recommendations for prevention and control of influenza in children, 2013\u20132014. Pediatrics. 2013;132(4):e1089\u2013e1104."},{"issue":"1","key":"i1551-6776-25-7-654-b3","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza--recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","year":"2011","unstructured":"Centers for Disease Control and Prevention (CDC).\n          Antiviral agents for the treatment and chemoprophylaxis of influenza--recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1\u201328."},{"issue":"8","key":"i1551-6776-25-7-654-b4","series-title":"Clin Infect Dis","first-page":"1003","article-title":"Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management; clinical practice guidelines of the Infectious Diseases Society of America","volume":"48","year":"2009","unstructured":"Harper\n              SA\n            , BradleyJS, EnglundJA, \n          et al. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management; clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003\u20131032."},{"issue":"11","key":"i1551-6776-25-7-654-b5","series-title":"Pediatr Ann","first-page":"456","article-title":"Supraventricular tachycardia in infancy and childhood","volume":"43","year":"2014","unstructured":"Spearman\n              AD\n            , WilliamsP, Supraventricular tachycardia in infancy and childhood. Pediatr Ann. 2014;43(11):456\u2013460."},{"issue":"6","key":"i1551-6776-25-7-654-b6","series-title":"Int J Cardiol","first-page":"2397","article-title":"The cardiovascular manifestations of influenza: a systematic review","volume":"167","year":"2013","unstructured":"Estabragh\n              ZR\n            , MamasMA.\n          The cardiovascular manifestations of influenza: a systematic review. Int J Cardiol. 2013;167(6):2397\u20132403."},{"issue":"102","key":"i1551-6776-25-7-654-b7","series-title":"Prescrire Int","first-page":"167","article-title":"Oseltamivir: cardiac and visual disorders","volume":"18","year":"2009","unstructured":"Oseltamivir: cardiac and visual disorders.Prescrire Int. 2009;18(102):167."},{"issue":"suppl 3","key":"i1551-6776-25-7-654-b8","series-title":"Int J Infect Dis","first-page":"e374","article-title":"Suspected oseltamivir-induced bradycardia","volume":"14","year":"2010","unstructured":"Karplus\n              R\n            , SansetS, ZaidensteinR, SchneiderD, BerkovitchM.\n          Suspected oseltamivir-induced bradycardia. Int J Infect Dis. 2010;14(suppl 3):e374\u2013e375."},{"issue":"6","key":"i1551-6776-25-7-654-b9","series-title":"Clin Pharmacokinet","first-page":"471","article-title":"Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802","volume":"37","year":"1999","unstructured":"He\n              G\n            , MassarellaJ, WardP, Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.Clin Pharmacokinet. 1999;37(6):471\u2013484."},{"issue":"2","key":"i1551-6776-25-7-654-b10","series-title":"Clin Pharmacol Ther","first-page":"239","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","year":"1981","unstructured":"Naranjo\n              CA\n            , BustoU, SellersEM, \n          et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u2013245."},{"year":"2019","series-title":"Tamiflu (oseltamivir) [package insert]","key":"i1551-6776-25-7-654-b11","unstructured":"Tamiflu (oseltamivir) [package insert]. South San Francisco, CA: Genentech Inc; 2019."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/7\/article-p654.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/25\/7\/654\/2606053\/1551-6776-25_7_654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/7\/article-p654.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/25\/7\/article-p654.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:39:07Z","timestamp":1747355947000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/25\/7\/article-p654.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":11,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-25.7.654","relation":{},"ISSN":["1551-6776"],"issn-type":[{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}